It comes down to pharmacokinetics, individual biology, the specific medication being used, and a handful of factors that most providers never explain in detail
And a growing number are searching for natural alternatives that support similar metabolic mechanisms without a prescription, without weekly injections, and without the significant side effects that lead many patients to discontinue
If we recall that approximately 25% of total weight loss in persons with obesity is accounted for by FFM, the authors found that fat free mass accounted for 33%, 39%, and 25% of total weight loss for retatrutide ( Phase 2 data only, not yet FDA approved), semaglutide and tirzepatide respectively whereas fat mass loss accounted for 67%, 61%, and 75% respectively
Pricing is another major differentiator